Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Phase 1

Active, not recruiting

Conditions: Colorectal Cancer
Gastroesophageal Cancer
Renal Cell Carcinoma

Interventions: Drug: Gevokizumab
Drug: Bevacizumab
Drug: Ramucirumab
Drug: Cabozantinib
Drug: Modified FOLFOX6
Drug: FOLFIRI
Drug: Paclitaxel

First Posted Date: 2019-01-10

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 167

Registration Number: NCT03798626

Locations: 🇺🇸
University of California LA, Los Angeles, California, United States
🇺🇸
WA Uni School Of Med, Saint Louis, Missouri, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 1 locations

Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: sacubitril/valsartan

First Posted Date: 2018-12-24

Last Posted Date: 2024-07-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 216

Registration Number: NCT03785405

Locations: 🇹🇷
Novartis Investigative Site, Konak-Izmir, Turkey
🇺🇸
Mayo Clinic - Rochester, Rochester, Minnesota, United States

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

Phase 2

Terminated

Conditions: Liver Transplant Rejection

Interventions: Drug: Tacrolimus - MMF - corticosteroids
Biological: CFZ533

First Posted Date: 2018-12-19

Last Posted Date: 2024-07-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 128

Registration Number: NCT03781414

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant

Phase 2

Completed

Conditions: Graft vs Host Disease

Interventions: Drug: INC424

First Posted Date: 2018-12-12

Last Posted Date: 2024-12-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 46

Registration Number: NCT03774082

Locations: 🇹🇷
Novartis Investigative Site, Antalya, Turkey

An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

Phase 3

Completed

Conditions: Juvenile Psoriatic Arthritis
Enthesitis Related Arthritis

Interventions: Drug: AIN457

First Posted Date: 2018-12-07

Last Posted Date: 2024-11-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 56

Registration Number: NCT03769168

Locations: 🇺🇸
St Lukes Intermountain Research Center, Boise, Idaho, United States
🇺🇸
Cincinnati Childrens Hospital, Cincinnati, Ohio, United States
🇺🇸
Legacy Emanuel Research Hospital Portland, Portland, Oregon, United States

and more 1 locations

A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis

Phase 2

Completed

Conditions: Giant Cell Arteritis

Interventions: Drug: Secukinumab 300 mg, s.c.
Drug: Placebo
Drug: Prednisolone

First Posted Date: 2018-12-05

Last Posted Date: 2023-08-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 52

Registration Number: NCT03765788

Locations: 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany

HDM201 Added to CT in R/R or Newly Diagnosed AML

Phase 1

Withdrawn

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: HDM201
Drug: cytarabine
Drug: anthracycline
Drug: liposomal cytarabine/daunorubicin
Drug: posaconazole
Drug: midazolam
Drug: midostaurin

First Posted Date: 2018-11-30

Last Posted Date: 2020-01-09

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03760445

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

Phase 2

Completed

Conditions: Depressive Disorder, Treatment-Resistant

Interventions: Drug: MIJ821
Drug: Placebo
Drug: Ketamine

First Posted Date: 2018-11-28

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 70

Registration Number: NCT03756129

Locations: 🇪🇸
Novartis Investigative Site, Barcelona, Spain

Study of Efficacy of PEAR-004 in Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Device: PEAR-004
Device: Sham

First Posted Date: 2018-11-23

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 112

Registration Number: NCT03751280

Locations: 🇺🇸
Novartis Investigative Site, Albuquerque, New Mexico, United States

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Phase 1

Terminated

Conditions: Triple Negative Breast Cancer (TNBC)

Interventions: Biological: spartalizumab
Biological: LAG525
Biological: MCS110
Biological: canakinumab
Drug: NIR178
Drug: capmatinib

First Posted Date: 2018-11-15

Last Posted Date: 2024-01-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 64

Registration Number: NCT03742349

Locations: 🇺🇸
Columbia University Medical Center- New York Presbyterian Columbia, New York, New York, United States
🇪🇸
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
🇺🇸
Sarah Cannon Research Institute Sarah Cannon Research, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy